Welcome to Skin cancer and Mesothelioma Cancer

Mesothelioma Cancer, Melanoma Cancer, Mesothelioma, Mesothelioma Lawyer
==================================================================

Saturday, June 21, 2008

Fwd: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 17;
Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA, Osieka R, Buettner R, Hillen HF, Ramaekers FC

Unknown primary adenocarcinoma (UPA) comprises a group of heterogeneous cancers of great clinical and biological interest. UPA presents as metastatic disease without a detectable primary site after medical workup. Here we investigated whether or not a clonal relationship exists between multiple tumors within individual UPA patients. A molecular resemblance would argue for an early clonal outgrowth of tumor cells from the primary lesion, a mutual feature observed within this group of neoplasms. In 14 patients with UPA multiple tumors, obtained at autopsy, were analyzed by molecular allelotyping and immunohistochemistry. In addition, tumors of 4 patients could be analyzed by comparative genomic hybridization (CGH). Similar genetic and phenotypic profiles were used as indicator for a clonal relationship, whereas different profiles implicate independent tumors. The molecular data indicated that the multiple lesions in the 14 UPA patients, including the primary tumors, are clonally related. In agreement with the theory of tumor progression, some metastatic lesions showed additional genetic alterations besides the characteristics that were shared with the primary tumor. Furthermore, 8 UPA patients had tumors with a high frequency of allelic loss and/or imbalance (FALI; 43-71%), while 6 patients demonstrated a lower FALI (14-29%), suggesting the occurrence of chromosomal instability in the former group. Our data provide molecular evidence for a clonal relationship between multiple metastases and the primary tumor within individual UPA patients, independent of the anatomical origin of the cancer. This finding is in agreement with the suggestion that tumor progression is rapid in UPA patients, limiting the chance of clonal divergence. The identification of 2 groups of UPAs with either a high or low FALI indicates that chromosomal instability is not the only driving force behind early tumor cell dissemination. Thus, other molecular mechanisms must underlie the common biology of these tumors. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18561313
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jun 17;
Ruckhäberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M, Rody A

PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P

___
Source: http://www.hubmed.org/display.cgi?uids=18560890
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.
To: mesothelioma77@gmail.com


[1]Arch Surg. 2008 Jun; 143(6): 575-80; discussion 581
Manouras A, Markogiannakis H, Genetzakis M, Filippakis GM, Lagoudianakis EE, Kafiri G, Filis K, Zografos GC

HYPOTHESIS: The use of the electrothermal bipolar vessel sealing system is feasible, safe, and effective in modified radical mastectomy with axillary dissection in terms of lymph vessel sealing, hemostasis, and perioperative complications. DESIGN: Prospective study. SETTING: University surgical department. PATIENTS: Between January 1, 2003, and December 31, 2003, 60 patients with locally advanced breast cancer (T2 or T3) admitted for modified radical mastectomy with axillary dissection were included in this study. The entire procedure was performed by the same surgical team using the electrothermal bipolar vessel sealing system. MAIN OUTCOME MEASURES: Final outcome, operative time, hospitalization stay duration, intraoperative blood loss, postoperative mastectomy and axillary drainage volume and duration, and postoperative complications (seroma, bleeding, skin burn, hematoma, lymphedema, pneumothorax, and wound infection or necrosis). RESULTS: The mean (SD) intraoperative blood loss was 45 (12) mL, and the mean (SD) operative time was 105 (7) minutes. No postoperative bleeding, seroma, hematoma, lymphedema, or other complications occurred. The mean (SD) mastectomy and axillary drainage volumes were 20 (8) and 155 (35) mL, respectively, and the mean (SD) drainage durations were 1.3 (0.2) and 2.7 (0.5) days, respectively. The mean (SD) hospital stay was 3.7 (0.6) days. CONCLUSIONS: In this first report (to our knowledge) of modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system, the technique was feasible, safe, and effective. The device simplified the surgical procedure, while achieving efficient lymph vessel sealing and hemostasis. Compared with historical data regarding the conventional or harmonic scalpel, this technique seems to result in reduced operative time, perioperative blood loss, drainage volume and duration, and incidence of seroma or lymphedema. Prospective randomized controlled studies are necessary to evaluate the effect of this technique on perioperative complications.



___
Source: http://www.hubmed.org/display.cgi?uids=18559751
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)
To: mesothelioma77@gmail.com


An article in the July edition of The Lancet Oncologysuggests that a common treatment for liver cancer - radiofrequencyablation - can also be used to treat lung cancer. A team of Europeanand American researchers calls for randomized controlled trials inorder to more robustly investigate this minimally invasive procedurefor cancer treatment.

Fri, 20 Jun 2008 08:15:52 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11netr8lv/*http%3A//www.medicalnewstoday.com/articles/112052.php
--
 
 

Fwd: Antihormone therapy in recurrent metastatic breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Antihormone therapy in recurrent metastatic breast cancer.
To: mesothelioma77@gmail.com


[1]JAMA. 2008 Jun 18; 299(23): 2745; author reply 2745
Pritchard KI





___
Source: http://www.hubmed.org/display.cgi?uids=18559999
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)
To: mesothelioma77@gmail.com


WEDNESDAY, June 18 (HealthDay News) -- A minimally invasive procedure normally used to treat liver cancer also holds promise for lung cancer patients, according to a new study.

Wed, 18 Jun 2008 13:01:32 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12menkona/*http%3A//news.yahoo.com/s/hsn/20080618/hl_hsn/nonsurgicalapproachcantreatlungcancers
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)
To: mesothelioma77@gmail.com


BERLIN and SEATTLE, June 18, 2008 -- Epigenomics AG , a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it successfully completed a larger clinical study in its lung cancer program.

Wed, 18 Jun 2008 07:12:56 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11eqctkpc/*http%3A//biz.yahoo.com/pz/080618/144892.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc